Shareholders Await Payout as Vyant Bio Liquidation Drags On

The dissolution of biotechnology firm Vyant Bio continues to proceed at a slower pace than initially outlined. While shareholders approved the company’s wind-down in late 2023, they are still awaiting the promised liquidation distributions from the firm’s remaining assets.

A Timeline of Dissolution

Formerly focused on drug discovery for neurological disorders, Vyant Bio commenced its formal dissolution process in November 2023. This followed its delisting from the Nasdaq exchange in May 2023 and a subsequent move to over-the-counter trading. The company was formally dissolved on December 29, 2023, ending regular share trading. Since that date, shareholder rights have been confined to potential distributions from any remaining corporate assets.

Prior to the wind-down, the company sold off significant business segments to raise cash for the liquidation process and the intended shareholder payout. These disposals included the subsidiary vivoPharm and certain assets belonging to StemoniX.

Should investors sell immediately? Or is it worth buying Vyant Bio?

Delayed Distributions and a Worthless Stock

Company management had originally indicated that shareholders could expect payments in a range of $0.16 to $0.29 per share. An initial distribution was scheduled for the fourth quarter of 2024. However, as of March 2026, there has been no public confirmation that these funds have been disbursed. The expected deadline for the payout has long passed without any communication from the company regarding the completion of payments.

The equity’s performance mirrors this state of limbo. Having lost 100 percent of its value over the past year and with no trading volume, the stock is effectively worthless unless liquidation payments materialize. Some financial platforms still list the ticker symbol VYNT but have recorded no price quotations since the company’s formal dissolution.

For former equity holders, the situation remains unresolved. With the announced timeline for the initial distribution having elapsed without an execution update, attention is now focused on receiving official confirmation regarding the status of the estimated remaining funds.